Related Experiment Videos
Plasma-fibrinogen and thromboemboli after myocardial infarction
Lancet (London, England)
|November 27, 1976
Insights
High plasma-fibrinogen levels (over 750 mg/dl) in myocardial infarction patients indicate a risk for thromboembolism. Monitoring fibrinogen can identify at-risk individuals, potentially reducing complications with anticoagulation.
Area of Science:
- Cardiology
- Hematology
Background:
- Myocardial infarction (MI) survivors face risks of thromboembolic events.
- Identifying patients susceptible to post-MI thromboembolism is crucial for preventative strategies.
Purpose of the Study:
- To investigate the correlation between plasma-fibrinogen levels and the occurrence of non-fatal thromboemboli in patients following myocardial infarction.
- To assess the potential of plasma-fibrinogen monitoring as a risk stratification tool for post-MI thromboembolism.
Main Methods:
- A cohort of 120 patients with myocardial infarction was monitored.
- Plasma-fibrinogen levels were measured and correlated with the incidence of subsequent non-fatal thromboembolic events.
Main Results:
- Non-fatal thromboemboli were exclusively observed in patients whose plasma-fibrinogen levels surpassed 750 mg/dl.
- A clear threshold effect was identified, with levels above 750 mg/dl indicating significant risk.
Conclusions:
- Elevated plasma-fibrinogen ( > 750 mg/dl) is a strong indicator of thromboembolic risk after myocardial infarction.
- Monitoring plasma-fibrinogen levels can aid in identifying high-risk patients.
- Anticoagulant therapy may be beneficial in mitigating morbidity in these patients.
Abstract:
In 120 patients with myocardial infarction subsequent non-fatal thromboemboli occurred only in patients in whom plasma-fibrinogen had exceeded 750 mg/dl. It is suggested that patients at risk from thromboembolism after infarction can be identified by monitoring plasma-fibrinogen and that appropriate anticoagulation might reduce morbidity.